Bringing truly personalized cancer vaccination with tumour neoantigens to the clinic will require overcoming the challenges of optimized vaccine design, manufacturing and affordability, and identification of the most suitable clinical setting.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
A lentiviral vector targeting a KRAS neoepitope for cancer immunotherapy
Scientific Reports Open Access 02 July 2025
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Robbins, P. F. et al. Nat. Med. 19, 747–752 (2013).
Pardoll, D. M. Nat. Rev. Cancer 12, 252–264 (2012).
Sharma, P. & Allison, J. P. Science 348, 56–61 (2015).
Schumacher, T. N. & Schreiber, R. D. Science 348, 69–74 (2015).
Mcgranahan, N. et al. Science 351, 1463–1469 (2016).
Tran, E. et al. Science 350, 1387–1390 (2015).
Castle, J. C. et al. Cancer Res. 72, 1081–1091 (2012).
Kreiter, S. et al. Nature 520, 692–696 (2015).
Gubin, M. M. et al. Nature 515, 577–581 (2014).
Yadav, M. et al. Nature 515, 572–576 (2014).
Kreiter, S., Castle, J. C., Türeci, O. & Sahin, U. OncoImmunology 1, 768–769 (2012).
Carreno, B. M. et al. Science 348, 803–808 (2015).
Ott, P. A. et al. Nature 547, 217–221 (2017).
Sahin, U. et al. Nature 547, 222–226 (2017).
Löwer, M. et al. PLoS Comput. Biol. 8, e1002714 (2012).
Laumont, C. M. & Perreault, C. Cell. Mol. Life Sci. 75, 607–621 (2017).
Turajlic, S. et al. Lancet Oncol. 18, 1009–1021 (2017).
Balachandran, V. P. et al. Nature 551, 512–516 (2017).
Łuksza, M. et al. Nature 551, 517–520 (2017).
Khodadoust, M. S. et al. Nature 543, 723–727 (2017).
Abelin, J. G. et al. Immunity 46, 315–326 (2017).
Luo, H. et al. Bioinform. Biol. Insights https://doi.org/10.4137/BBI.S29466 (2015).
Kranz, L. M. et al. Nature 534, 396–401 (2016).
Harrison, R. P., Ruck, S., Rafiq, Q. A. & Medcalf, N. Biotechnol. Adv. 36, 345–357 (2018).
Kagermann, H. in Management of Permanent Change 23–45 (Springer Fachmedien Wiesbaden, 2015).
Türeci, O. et al. Clin. Cancer Res. 22, 1885–1896 (2016).
Chen, D. S. & Mellman, I. Nature 541, 321–330 (2017).
Melero, I. et al. Nat. Rev. Cancer 15, 457–72 (2015).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
U.S. and M.La. are employees at BioNTech AG (Mainz, Germany), a privately owned company developing individualized immunotherapies. U.S. is co-founder, stock owner and management board member of BioNTech AG. Ö.T., M.Lö., B.S., M.La., A.T. and U.S. are inventors on patents and patent applications, which are related to some of the technologies described in this article.
Rights and permissions
About this article
Cite this article
Türeci, Ö., Löwer, M., Schrörs, B. et al. Challenges towards the realization of individualized cancer vaccines. Nat Biomed Eng 2, 566–569 (2018). https://doi.org/10.1038/s41551-018-0266-2
Published:
Issue date:
DOI: https://doi.org/10.1038/s41551-018-0266-2
This article is cited by
-
A lentiviral vector targeting a KRAS neoepitope for cancer immunotherapy
Scientific Reports (2025)
-
Targeting public neoantigens for cancer immunotherapy
Nature Cancer (2021)
-
Advances in the development of personalized neoantigen-based therapeutic cancer vaccines
Nature Reviews Clinical Oncology (2021)
